
Opinion|Videos|May 9, 2025
The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC
Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Quality of Life Considerations
Key Themes:
- Balance of Efficacy and Toxicity: Weighing survival benefits against treatment-related adverse events
- Patient Preferences: Discussion of Asian study data showing some patients prefer monotherapy with potentially shorter survival over combination therapy
- Prophylactic Management: Importance of supportive care measures to mitigate toxicity
Notable Insights:
- Dr Dietrich: “Quality of life is important when it comes to treatment-related toxicity. But...a significant drop occurs at the time of cancer progression, and that’s probably the quality-of-life impairment that I’m most struggling with.” He argued that quality and quantity of life often align rather than contradict.
- Dr Piotrowska: Highlighted the importance of supportive care data, noting “we’re seeing a lot of data from studies looking at ways to support patients better” including the COCOON study for dermatologic toxicities and the SKIPPirr regimen for preventing infusion-related reactions.
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs
2
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
3
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
4
Relapsed/Refractory Multiple Myeloma: Applying Real-World Evidence to CAR T-Cell Therapy
5


